News Channels

22 Mar 2017 AVEO Announces First Patient Dosed in Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in Advanced RCC
22 Mar 2017 Akashi Therapeutics Receives FDA Clearance to Resume HT-100 Clinical Development
22 Mar 2017 Cue Biopharma Announces Selection of Lead Candidate Cue-101 Targeting Human Papillomavirus (HPV)-Associated Cancers
22 Mar 2017 AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Gaucher Disease
22 Mar 2017 Netris Pharma Starts Enrollment of First Clinical Study to Evaluate Drug Candidate Targeting Dependence Receptors
22 Mar 2017 Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067
22 Mar 2017 Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
22 Mar 2017 FDA Approves Xadago® (Safinamide) for Parkinson’s Disease (PD) Patients
22 Mar 2017 Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results in Patients Treated with HS-110 in Combination with a Checkpoint Inhibitor
22 Mar 2017 Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid
21 Mar 2017 Phase 1/2 Clinical Trial of Apexigen's APX005M in Combination with Pembrolizumab (Keytruda®) Opens for Metastatic Melanoma Patients
21 Mar 2017 EnGeneIC Doses First Patient in U.S. Phase 1 Clinical Study of Targeted EDV™ Nanocells in Recurrent Glioblastoma Multiforme
21 Mar 2017 Tarrex Biopharma Announces FDA Acceptance of IND Application for TX803 to Commence Phase I Clinical Trials in Colorectal Cancer Patients
21 Mar 2017 X-Chem and Ono Enter into Multi-Target Drug Discovery Collaboration
21 Mar 2017 WntResearch Announces Positive Results From Clinical Study With Drug Candidate Foxy-5
21 Mar 2017 Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667
21 Mar 2017 Syntimmune Announces Breakthrough Results of FcRn Inhibition Published in PNAS
21 Mar 2017 Pierre Fabre and H-Immune Announce Strategic Research Partnership to Develop Potentially Ground-Breaking Cancer Immunotherapies
21 Mar 2017 Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
20 Mar 2017 GeoVax Reports Promising Results for Zika Vaccine

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing